Edition:
United Kingdom

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

19.42USD
19 Oct 2017
Change (% chg)

-- (--)
Prev Close
$19.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
185,404
52-wk High
$24.12
52-wk Low
$12.10

Latest Key Developments (Source: Significant Developments)

Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals‍​
Thursday, 7 Sep 2017 

Sept 8 (Reuters) - Adamas Pharmaceuticals Inc :Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals as of August 29 - SEC filing .‍​.  Full Article

Adamas announces FDA approval of Gocovri as first and only medication for dyskinesia treatment in Parkinson’s disease patients
Thursday, 24 Aug 2017 

Aug 24 (Reuters) - Adamas Pharmaceuticals Inc :Adamas Pharmaceuticals Inc - ‍Gocovri is expected to be available in Q4, and formally launched in Jan 2018​.  Full Article

Adamas Pharmaceuticals Q2 loss per share $0.93
Tuesday, 8 Aug 2017 

Aug 8 (Reuters) - Adamas Pharmaceuticals Inc :Adamas reports recent achievements and second quarter 2017 financial results.Q2 loss per share $0.93.Q2 earnings per share view $-0.81 -- Thomson Reuters I/B/E/S.  Full Article

Adamas announces publication of ADS-5102 phase 3 EASE LID clinical trial in JAMA Neurology
Monday, 12 Jun 2017 

June 12 (Reuters) - Adamas Pharmaceuticals Inc :Adamas announces publication of ADS-5102 phase 3 EASE LID clinical trial in JAMA Neurology.Adamas Pharmaceuticals Inc - new drug application for ADS-5102 currently under FDA review with August 24, 2017 PDUFA date.  Full Article

Adamas presents positive phase 1A data
Monday, 22 May 2017 

May 22 (Reuters) - Adamas Pharmaceuticals Inc ::Adamas presents positive phase 1A data of ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy.Adamas Pharmaceuticals - phase 1 results show ADS-4101 is better tolerated in healthy volunteers than equivalent doses of vimpat.Says multi-dose phase 1b steady state study ongoing, with topline data expected in Q3 2017.Adamas Pharmaceuticals - data from study showed all four formulations of ADS-4101 to be safe and well tolerated when compared to vimpat-treated group.  Full Article

Adamas Pharmaceuticals enters into sales agreement with Cowen
Thursday, 11 May 2017 

May 11 (Reuters) - Adamas Pharmaceuticals Inc :Entered into sales agreement with Cowen and co, relating to potential common stock offering of up to $50 million of its shares.  Full Article

Adamas reports Q1 loss per share $0.72
Tuesday, 9 May 2017 

May 9 (Reuters) - Adamas Pharmaceuticals Inc :Adamas reports recent achievements and first quarter 2017 financial results.Q1 loss per share $0.72.Q1 earnings per share view $-0.71 -- Thomson Reuters I/B/E/S.  Full Article

Adamas reports Q4 loss per share $0.68
Tuesday, 28 Feb 2017 

Adamas Pharmaceuticals Inc : Adamas reports recent achievements and financial results for the fourth quarter and full-year 2016 . Q4 loss per share $0.68 . Q4 earnings per share view $-0.80 -- Thomson Reuters I/B/E/S .Adamas pharmaceuticals inc - qtrly loss per share $0.68.  Full Article

Adamas to present new ADS-5102 data from phase 2 trial
Friday, 17 Feb 2017 

Adamas Pharmaceuticals Inc : Adamas to present new ADS-5102 data from phase 2 trial in walking impairment associated with multiple sclerosis at actrims forum 2017 . Adamas Pharmaceuticals- in study, patients on ads-5102 showed approximate 17 percent placebo-adjusted improvement in walking speed in timed 25 foot walk test . Adamas Pharmaceuticals Inc - in study, patients on ADS-5102 showed approximate three second placebo-adjusted improvement in timed up and go (TUG) test . Adamas Pharmaceuticals Inc - ADS-5102 was generally well tolerated . Adamas Pharmaceuticals Inc - five ADS-5102 patients and no placebo patients discontinued treatment due to AES .Adamas Pharmaceuticals Inc - most frequent adverse events (AES) reported in ads-5102 treatment group were dry mouth, constipation and insomnia.  Full Article

Adamas announces FDA acceptance of ADS-5102 new drug application
Friday, 6 Jan 2017 

Adamas Pharmaceuticals Inc : Adamas announces FDA acceptance of ADS-5102 new drug application for the treatment of levodopa-induced dyskinesia in patients with parkinson's disease .Adamas Pharmaceuticals Inc - PDUFA action date set for August 24, 2017.  Full Article

BRIEF-Adamas appoints Mardi C. Dier to its board of directors

* Adamas appoints Mardi C. Dier to its board of directors Source text for Eikon: Further company coverage: